- Silverback Therapeutics (SBTX) shares started the first day of trading up 38% from the $21 pricing.
- The upsized offering had 11.5M shares and raised $241.5M.
- Silverback developed its ImmunoTAC technology platform to "develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases."
- https://seekingalpha.com/news/3641816-immuno-oncology-company-silverback-therapeutics-surges-38-after-market-debut
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.